Skip to content
Peptigraph home

Ecnoglutide Phase 3 trial (NCT05680129)

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
623
actual
Start
10 Jan 2023 (actual)
Primary completion
3 Jul 2024 (actual)
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Design

Arms and doses

NCT05680129 study arms
ArmTypeInterventionsDescription
B1: XW003+METExperimentalDrug: Ecnoglutide high dosage; Drug: MetforminHigh dosage of XW003 once weekly
B2: XW003+METExperimentalDrug: Ecnoglutide low dosage; Drug: MetforminLow dosage of XW003 once weekly
B3: Dulaglutide+METActive comparatorDrug: Dulaglutide; Drug: Metformin1.5mg Dulaglutide once weekly
Endpoints

Primary endpoint

NCT05680129 primary outcomes
MeasureTime frame
Change from baseline in HbA1cBaseline, week 32
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05680129 secondary outcomes
MeasureTime frame
Change from baseline in HbA1cBaseline, Week 5, Week 9, Week 13, Week 17, Week 25, Week 43 and Week 52
Change from baseline in fasting plasma glucose (FPG)Baseline, Week 32 and Week 52
Change from baseline in lipid panelBaseline, Week 32 and Week 52
Change from baseline in body weightBaseline, Week 32 and Week 52
Pharmacokinetics: plasma trough level of XW003Baseline, Day 29, Day 57, Day 85, Day 224, Day 364 and Day 399
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of XW003 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by MetforminClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.